Immunosuppression after liver transplantation;Immunosuppression après transplantation hépatique

Presse Medicale

Volumn 38, Issue 9, 2009, Pages 1307-1313

  Calmus, Yvon ^a  

^a université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; JANUS KINASE 3 INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ODULIMOMAB; OKT 3; PROTEIN KINASE C INHIBITOR; RAPAMYCIN; RITUXIMAB; SOTRASTAURIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ALOPECIA; AREA UNDER THE CURVE; ARTHROPATHY; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GINGIVA HYPERTROPHY; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER CANCER; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; PATIENT MONITORING; SHORT SURVEY; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTIGEN-PRESENTING CELLS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; POSTOPERATIVE CARE; T-LYMPHOCYTES, REGULATORY;

EID: 69549084441     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.06.004     Document Type: Short Survey

References (22)

1. Conti F., Morelon E., and Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 39 (2003) 664-678
2. Baião A.M., Wowk P.F., Sandrin-Garcia P., Junta C.M., Fachin A.L., Mello S.S., et al. cDNA microarray analysis of cyclosporin A (CsA)-treated human peripheral blood mononuclear cells reveal modulation of genes associated with apoptosis, cell-cycle regulation and DNA repair. Mol Cell Biochem 304 (2007) 235-241
3. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 18:CD005161.
4. Levy G., Schmidli H., Punch J., Tuttle-Newhall E., Mayer D., Neuhaus P., et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 12 (2006) 1640-1648
5. Satterthwaite R., Aswad S., and Sunga V. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65 (1998) 446-449
6. Créput C., Blandin F., Deroure B., Roche B., Saliba F., Charpentier B., et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 13 (2007) 1004-1010
7. Morard I., Dumortier J., Spahr L., Hadengue A., Majno P., Morel P., et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 13 (2007) 658-664
8. Tredger J.M., Brown N.W., Adams J., Gonde C.E., Dhawan A., Rela M., et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 10 (2004) 492-502
9. Le Meur Y., Büchler M., Thierry A., Caillard S., Villemain F., Lavaud S., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7 (2007) 2496-2503
10. Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Campsen J., Skibba A., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14 (2008) 633-638
11. Kremers W.K., Devarbhavi H.C., Wiesner R.H., Krom R.A., Macon W.R., and Habermann T.M. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6 (2006) 1017-1024
12. Calmus Y., and Pageaux G. Insuffisance rénale après transplantation hépatique. Press Med 38 (2009) 1314-1318
13. Duvoux C. De novo tumours after liver transplantation in adults. What is the actual risk ?. J Hepatol 34 (2001) 161-164
14. Yabu J.M., and Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol. 27 (2007) 479-486
15. Salvadori M., Budde K., Charpentier B., Klempnauer J., Nashan B., Pallardo L.M., et al., FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6 (2006) 2912-2921
16. Changelian P.S., Moshinsky D., Kuhn C.F., Flanagan M.E., Munchhof M.J., Harris T.M., et al. The specificity of JAK3 kinase inhibitors. Blood 111 (2008) 2155-2157
17. Tryphonopoulos P., Madariaga J.R., Kato T., Nishida S., Levi D.M., Moon J., et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 37 (2005) 1203-1204
18. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al., Belatacept study group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 453 (2005) 770-781
19. Vincenti F., Mendez R., Pescovitz M., Rajagopalan P.R., Wilkinson A.H., Butt K., et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 7 (2007) 1770-1777
20. Lev-Tov H., and Hadi S. Alefacept - a drug review. Rev Recent Clin Trials 1 (2006) 163-164
21. Eksteen B., and Neuberger J.M. Mechanisms of disease: the evolving understanding of liver allograft rejection. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 209-219
22. Chavez H., Beaudreuil S., Abbed K., Taoufic Y., Kriaa F., Charpentier B., et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 17 (2007) 243-248